1. |
骆琳, 刘建华, 吴丽娜. 特发性膜性肾病预后影响因素的研究进展. 中华肾脏病杂志, 2019, 35(1): 70-76.
|
2. |
Polanco N, Gutiérrez E, Covarsí A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol, 2010, 21(4): 697-704.
|
3. |
Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med, 2009, 361(1): 11-21.
|
4. |
张雅琪, 郝亚宁, 冯学亮, 等. 单中心特发性膜性肾病发病趋势及与血清 PLA2R 抗体的相关性分析. 中华肾脏病杂志, 2016, 32(9): 647-652.
|
5. |
庄永泽, 刘敏. 血清抗 PLA2R 抗体水平与成人特发性膜性肾病临床病理的相关性研究. 中国中西医结合肾病杂志, 2019, 20(12): 1068-1072.
|
6. |
陈瑞颖, 鲁鉴达, 谢琼虹, 等. 成人磷脂酶 A2 受体相关特发性膜性肾病的自然病程和治疗反应的影响因素. 中华肾脏病杂志, 2019, 35(1): 1-8.
|
7. |
李幼奇, 刘珍珍, 林克宣, 等. 肾组织中磷脂酶 A2 受体抗原的表达与特发性膜性肾病的临床及预后的关系. 中华肾脏病杂志, 2018, 34(9): 661-666.
|
8. |
Hill PA, Mcrae JL, Dwyer KM. PLA2R and membranous nephropathy: a 3 year prospective Australian study. Nephrology (Carlton), 2016, 21(5): 397-403.
|
9. |
王丹, 翟俊霞, 牟振云, 等. Meta 分析中的异质性及其处理方法. 中国循证医学杂志, 2009, 9(10): 1115-1118.
|
10. |
周广宇, 郭莹, 张力, 等. 他克莫司联合激素治疗特发性膜性肾病疗效及其抗 PLA2R 抗体对治疗的反应. 吉林大学学报(医学版), 2016, 42(5): 937-941.
|
11. |
张义德, 戴厚永, 袁莉, 等. 抗磷脂酶 A2 受体抗体在特发性膜性肾病诊疗中的意义. 国际泌尿系统杂志, 2017, 37(6): 896-899.
|
12. |
徐亚沛, 任蕾, 孙晓芳, 等. 特发性膜性肾病患者血清抗 PLA2R 抗体表达与免疫治疗效果的关系研究. 河南医学研究, 2017, 26(12): 2119-2122.
|
13. |
王旭童, 刘东伟, 刘风勋, 等. 特发性膜性肾病患者的临床病理特点及预后分析. 中国实用医刊, 2018, 45(4): 85-89.
|
14. |
周俊, 罗素珊, 潘海燕. 血清抗磷脂酶 A2 受体抗体表达与特发膜性肾病相关性. 青岛大学学报(医学版), 2018, 54(4): 439-442.
|
15. |
李强, 张蓓茹, 何平, 等. 血清 PLA2R 抗体检测在特发性膜性肾病临床及治疗反应评价中的应用(附 250 例报告). 中国实用内科杂志, 2018, 38(12): 1173-1176.
|
16. |
李正东, 张任. 血清学 PLA2R 抗体和 THSD7A 抗体检测辅助诊断特发性膜性肾病及对评估疗效和预后的价值研究. 中国煤炭工业医学杂志, 2019, 22(2): 149-157.
|
17. |
徐磊, 岳妍秋, 薛娇, 等. 抗磷脂酶 A2 受体抗体水平与原发性膜性肾病患者病情及治疗预后的相关性. 国际医药卫生导报, 2020, 26(15): 2254-2257.
|
18. |
Oh YJ, Yang SH, Kim DK, et al. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS One, 2013, 8(4): e62151.
|
19. |
Hoxha E, Harendza S, Pinnschmidt H, et al. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system. PLoS One, 2014, 9(10): e110681.
|
20. |
Timmermans SA, Abdul Hamid MA, Cohen Tervaert JW, et al. Anti-PLA2R antibodies as a prognostic factor in PLA2R-Related membranous nephropathy. Am J Nephrol, 2015, 42(1): 70-77.
|
21. |
Kim YG, Choi YW, Kim SY, et al. Anti-phospholipase A2 receptor antibody as prognostic indicator in idiopathic membranous nephropathy. Am J Nephrol, 2015, 42(3): 250-257.
|
22. |
Pourcine F, Dahan K, Mihout F, et al. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: a single-centre study over 14 years. PLoS One, 2017, 12(3): e0173201.
|
23. |
Provatopoulou S, Stangou M. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy: a retrospective cohort study. Rom J Intern Med, 2019, 57(2): 141-150.
|
24. |
Yin P, Wang J, Liang W, et al. Outcomes of primary membranous nephropathy based on serum anti-phospholipase A2 receptor antibodies and glomerular phospholipase A2 receptor antigen status: a retrospective cohort study. Ren Fail, 2020, 42(1): 675-683.
|
25. |
Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol, 2017, 12(6): 983-997.
|
26. |
Du Y, Li JH, He F, et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis. PLoS One, 2014, 9(8): e104936.
|
27. |
Wu X, Liu L, Guo Y, et al. Clinical value of a serum anti-PLA2R antibody in the diagnosis and monitoring of primary membranous nephropathy in adults. Int J Nephrol Renovasc Dis, 2018, 11: 241-247.
|
28. |
Rodas LM, Matas-García A, Barros X, et al. Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy. Clin Kidney J, 2019, 12(1): 36-41.
|
29. |
Bech AP, Hofstra JM, Brenchley PE, et al. Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol, 2014, 9(8): 1386-1392.
|
30. |
Ramachandran R, Yadav AK, Kumar V, et al. Temporal association between PLA2R antibodies and clinical outcomes in primary membranous nephropathy. Kidney Int Rep, 2017, 3(1): 142-147.
|
31. |
Hoxha E, Thiele I, Zahner G, et al. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Socf Nephrol, 2014, 25(6): 1357-1366.
|
32. |
褚晓鑫, 徐秀, 何晓峰, 等. 血清磷脂酶 A2 受体抗体在特发性膜性肾病缓解中的价值. 中华肾脏病杂志, 2018, 34(10): 752-758.
|
33. |
胡广, 眭维国. 成人特发性膜性肾病发病机制及诊疗研究新进展. 国际泌尿系统杂志, 2019, 39(4): 721-723.
|
34. |
蒋真斌, 蔡美顺, 董葆, 等. 适合中国人的抗磷脂酶 A2 受体抗体临界值的界定. 中华肾脏病杂志, 2020, 36(5): 379-384.
|
35. |
王蒙, 王力宁, 刘楠, 等. 血清抗 PLA2R 抗体水平对特发性膜性肾病的诊断及预后评估. 中国实用内科杂志, 2020, 40(2): 153-157.
|